Oncolytics Biotech Inc ONCY

CAR-T update

[Noteable]

September 27, 2023 -  AbbVie terminates its collaboration and license agreement with Caribou focused on advancing allogeneic CAR-T therapeutics for two unspecified AbbVie programs.

Caribou revealed in its SEC filing on Tuesday that AbbVie has “elected to not advance these two programs.” Following the contract’s termination, all licenses granted under the agreement will also end. 

Caribous CRISPR-based genome editing tools use an RNA guide molecule to help locate its target DNA sequence

Earlier this week, the Abbvie also terminated its contract with Maryland- and Shanghai-based I-Mab. The partners were previously working on the anti-CD47 antibody lemzoparlimab, which they had been developing for myelodysplastic syndrome and acute myeloid leukemia.

https://www.biospace.com/article/abbvie-terminates-caribou-car-t-contract-in-culling-of-cancer-pipeline/

[Noteable]

Caribou is focused on an internal pipeline led by allogeneic CAR-T cell therapies against CD19 and BCMA. Both candidates are in the clinic and could provide an off-the-shelf alternative to existing cell therapies such as Gilead’s Yescarta and Johnson & Johnson’s Carvykti. Pfizer stepped up to help fund the pipeline in July, investing $25 million in Caribou. The biotech earmarked the cash for

[Noteable]

September 27, 2023 -  Pfizer purchases US$25 Million of Caribou common shares. Rachel Haurwitz, PhD, Caribou’s president and chief executive officer said “We are actively advancing our allogeneic CAR-T cell therapy pipeline and look forward to providing updates from all of our [P1/2] programs over the next six months.  https://investor.cariboubio.com/news-releases/news-release

[Noteable]

September 30, 2023 - New York Post The out-of-pocket infusion price can range from $375,000 to $475,000 per person. Big pharma companies like AstraZeneca and Novartis are already conducting trials on off-the-shelf technology. Another development that could affect the staggering costs is transforming the treatment from a lengthy (and costly) hospital visit into an

[Noteable]

July 05, 2023 - Genetic Engineering & Biotechnology News (GEN) Vaccine boosts CAR T cell therapy  for solid tumors “Mechanistically, we found that the enhanced production of IFN-γ by vaccine-boosted CAR T cells was a major contributor to AS” the team noted. “Vaccine-boosted CAR T promoted dendritic cell (DC) recruitment to tumors, increased tumor antigen uptake

[jh1970]

Market cap Caribou is 3x bigger then ONC today. How is this possible that big pharmas still not trying to buyout ONC? No leaks no rumors. My second post today ever but holding shares  strong more then 20 years starting from Synsorb failure.

[Noteable]

Stuff is happening in bringing pelareorep into a Phase 3 PanCan supported clinical trial in metastatic pancreatic cancer in combination with paclitaxel and the CPI Tecentriq. With earlier Phase 2 GOBLET-1 results reporting that pelareorep demonstrated a 69% ORR over paclitaxel alone, ESMO will further report on these findings and set the stage for the filing for an Accelerated Approval as the ONCY

[fox7mf]

Stuff is happening. Stuff is happening. That's all we ever hear, but never see proof of said stuff happening. The SP remains mired in muck and there are never any juicy BP rumors concerning a purchase of Oncy. It's always wait another 90 days with this lot. GL.

[Buckhenry]

Any dissenting posts will not be tolerated here. It does not fit into the forever pumpers narrative and they are like the Baptists in heaven... they think they are the only ones here. And remember..  The beatings will continue until morale improves 

[Azzak34]

They are tolerated, they're just argued with. Same way you argue with positive, informative posts. Your only argument is that it hasn't happened yet or before. There's lots going on that hasn't happened yet or before.  Share price stinks and no one is happy about it. Doesn't change the data and information about Pela's standing and potential. 

[Noteable]

December 07, 2023 - Supplemental CAR-T work at Mayo Clinic was released recently using an OV which administered systemically before the standard treatment, which typically includes limb amputation and chemotherapy, and paves the way for further investigations into dose modification and combination therapy strategies with CAR-T therapy + OVs for the treatment of sarcomas. https

[Noteable]

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=35702352

[Noteable]

CAR-T explanation obtained from a post on stocktwits ...   https://www.youtube.com/watch?v=CxxuqIDyF_I&ab_channel=PeterMacCallumCancerCentre

[Noteable]

UCLA is another step closer in the development of an “off-the-self“ allogeneic CAR-T therapy. When combined with ONCYs pelareorep CAR-T durability is enhanced in the treatment of solid tumors. https://www.regmednet.com/breaking-new-ground-on-an-allogeneic-immunotherapy/

[Noteable]

December 15, 2023 - The FDA has placed a clinical hold on three of CARsgen Therapeutics’  CAR-T cell therapy candidates following an inspection of the Chinese biotech’s manufacturing facility in Durham, North Carolina.  According to CARsgen, the clinical hold on its products are due to chemistry, manufacturing, and controls-related “questions” that arose due to the FDA

[Noteable]

January 23, 2024 -  FDA Calls for Boxed Warnings on CAR-T Therapies Regarding Secondary Cancer Risks  All six commercial CAR-T therapies will be affected, including J&J’s Legend Biotech-partnered Carvykti (ciltacabtagene autoleucel), Novartis’ Kymriah (tisagenlecleucel), BMS’s Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) and Gilead’s Yescarta

[canadafan]

Oncolytics had very successful pre- clinical ( lab based) cat- t results. showing complete recovery, after a Pala booster. That was a long time ago. It was discussed that there were multiple pharma interest in trying studies with their specific CAR-t,  As was described by the now exited Andrew G,  ONC was looking to recieve royalties based on the up- use of the CAR-T , product. All

[Noteable]

And you believed everything that Andrew de G was saying? Give your head a shake.

[inthno]

The thought that Canadafan is sugguesting that onc could be taken private (or BO, partnership) is scarey as I was a shareholder in a company that was taken private and it only serves the purpose of whomever is taking it private and present managment and that is just a fact. As shareholders we need to make sure that this does not happen as it could be done with a low money raise and low sp (would

[Noteable]

 Canadafan is a loser and an admitted trader in ONCY.

[canadafan]

Not sure why the name calling. looser? in what context? Admitted trader? Yes in the past 20+ years , I have bought & sold shares of onc. in the early days. Had a few hundred shares. Sold & never owned until Matt took over from Brad T. BTW, since 2019 , I have never held zero shares.  meaning, I have been a continuous  shareholder for 5 years. I buy on dips. Trim a small% on

[Noteable]

Read my post. https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=35841583

[Buckhenry]

Decension among the troops. What is this site coming to... I think all of the pumpers are full of sheet as a Christmas turkey. I only read the posts when I'm in the toilet ... laughing helps my bowels move easier!!!!!

[Noteable]

O'henry ... Judging by your analogy, only you would serve a Christmas turkey that is ful o' she*at 

[Azzak34]

**Descension** Bucky, put the extra effort in while you're dropping anchor and spell check. 

[Snowdrift]

Sorry Azzak, but it's DISSENSION.

[Azzak34]

Yeah I wouldn't disagree actually in that context. I would say, however, that we both posted words that exist. Buckster made up a whole new one. 

[Noteable]

January 25, 2024 -  Engineered viruses are the dominant vectors in current gene therapy (CAR-T) clinical studies. A plethora of viral vectors including adenovirus (Ad), adenoassociated virus (AAV), and herpes simplex virus (HSV) have become subjects of concern to the FDA since the risk of the emergence of a new cancer - caused by genomic integration from these engineered 

[Noteable]

February 02, 2024 - The FDA has decided on a date for a highly anticipated advisory committee meeting to discuss applications for Bristol Myers' Abecma and Johnson & Johnson's Carvykti. The FDA will convene its Oncologic Drugs Advisory Committee (ODAC) for a full-day meeting on March 15 to review the applications for Bristol Myers Squibb and 2seventy bio’s Abecma and J&J and

[Noteable]

March 12, 2024 - Mustang Bio and City of Hope’s chimeric antigen receptor T-cell (CAR-T) therapy for recurrent glioblastoma has resulted in stable disease or better in half of the subjects in a phase 1 clinical trial, including one patient whose cancer has not recurred for more than five years.  The trial, described March 7 in Nature Medicine, is the largest reported so far on a CAR-T

[Noteable]

March 12, 2024 - Ahead of a high-stakes FDA meeting to review CAR-T data in multiple myeloma, Legend Biotech CEO Ying Huang, Ph.D., laid out some of his expectations about the event. For one, the Legend CEO expects that the advisory committee meeting will largely focus on overall survival efficacy results, rather than the FDA’s CAR-T safety probe that’s playing out in parallel to

[Noteable]

https://www.fiercepharma.com/pharma/fda-flags-early-deaths-car-t-myeloma-trials-jj-and-legends-carvykti-bristol-myers-abecma

[Noteable]

April 12, 2024 -  Roche subsidiary Genentech has terminated a cell therapy partnership with Adaptimmune Therapeutics worth up to $3 billion biobucks. The collaboration, inked in 2021, was a licensing deal focused on the development of two types of allogeneic T-cell therapies: off-the-shelf therapies directed to up to five targets and personalized therapies using αβ T-cell

[Noteable]

April 19, 2024 - The FDA announced on Thursday that it will officially require an update to the boxed warnings of CAR-T cell therapies, which should now also alert patients and prescribers to a heightened risk of developing secondary T cell malignancies. All six commercially available CAR-T therapies will be affected, including Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) and

[Noteable]

https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous

[CMHarring218431]

This is BIG it would seem!

[Noteable]

April 30, 2024 - Among the layoffs that Bristol Myers Squibb announced today are teams in Washington state, including staffers working on its CAR-T therapy Breyanzi, according to sources familiar with BMS's layoff decisions. This decision follows a FiercePharma January 2024 report of CAR-T infrastructure bottleneck issues. " Since the FDA approved the first CAR-T therapy back in

[Noteable]

Oncolytic virus (reovirus/ pelareorep) optimizes CAR-T cell therapy for solid tumors This study and others are among the first to advance this therapy for solid tumors. The field of CAR-T cell therapy is advancing rapidly as researchers aim to learn new applications.  https://www.mayoclinic.org/medical-professionals/cancer/news/oncolytic-virus-optimizes-car-t-cell-therapy-for-solid-tumors

[Noteable]

"We saw this added benefit that the CAR-T cells recognized the antigens expressed by the virus," says Dr. Richard Vile. "That meant if we readministered the virus when the tumor started to return, the T cells were reactivated much like in response to a traditional vaccine."

[Noteable]

16th Annual International Oncolytic Virotherapy Conference 27 – 30 October 2024 - Rotterdam, the Netherlands  Monday October 28, 2024 - 09:30-10:30 am -  Plenary Presentation Session 1 - Intravenous Pelareorep Combined with the PD-L1 Inhibitor Atezolizumab Demonstrates Promising Efficacy in Pancreatic and Anal Cancer in the Phase 1/2 GOBLET Study (by Thomas Heinemans) 

[Noteable]

May 23, 2024 - A new survey and report from IQVIA, timed to come out alongside this year’s American Society of Clinical Oncology (ASCO) cancer congress abstracts drop, asked 100 CAR-T oncologists about how well they felt informed about cell therapies. Their biggest concern? Most oncologists who refer patients for CAR-T, coming in at 61%, spoke of a broad need for “more information about CAR

[Noteable]

The immunosuppressive tumor microenvironment and physical tumor barriers, such as the tumor stroma, can restrict the infiltration and migration of CAR-T cells, limiting their effectiveness in treating solid tumors. One main reason is the lack of relevant receptors on CAR-T cells that match the chemokines secreted by solid tumors, which hinders their homing ability to the tumor site.  ONCY

[Noteable]

September 03, 2024 - Arsenal Biosciences, the CAR-T cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery as the biotech sets out to build the biggest—and best—house on the block.  The oversubscribed series C fundraise includes new investors Regeneron Ventures, Arch Venture Partners and NVIDIA’s NVentures, among others